Evidence map›Paper›PMID 34907481›Full record

ArticleJournal of molecular modeling2021

Selectivity mechanism of phosphodiesterase isoform inhibitor through in silico investigations.

Junhao Huang, Baichun Hu, Ziqi Xu, Yunxia Ye, Huibin Wang, Shuxiang Wang, Zhilong Liu, Jian Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular modeling, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Junhao Huang *Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China.
Baichun Hu *Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China.
Ziqi XuSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China.
Yunxia YeSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China.
Huibin WangSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China.
Shuxiang WangSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China.
Zhilong LiuSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China.
Jian WangKey Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China. jianwang@syphu.edu.cn.ORCID http://orcid.org/0000-0002-9589-4056
Shenyang Pharmaceutical University · CN

Funding

Education Department of Liaoning 2020LJC05Overseas Expertise Introduction Project for Discipline Innovation D20029Program for Innovative Talents of Higher Education of Liaoning 2012520005Undergraduate Innovative Experiment Program 202010163011
6 · The paper itself

Abstract

Understanding the selectivity mechanism of inhibitors towards homology proteins helps to design selective candidates. Phosphodiesterase (PDE) family members act in the degradation of cAMP and cGMP, among which some isoforms such as PDE9A are attracting interest for Alzheimer's disease treatment, while PDE10A is used as target for treating schizophrenia. In this study, computational methods were used to investigate the major features of PDE9A/10A, with the purpose to provide deep understanding of the molecular mechanism of selective inhibition towards these two isoforms. Our result revealed that two conserved residues Gln453 and Phe456 were proven to be crucial for the binding affinity and inhibitory selectivity of PDE9A inhibitors. In addition, the high-affinity PDE9A inhibitors always interact with the conservative hydrophobic pocket as well as Tyr424 and Ala452 of PDE9A, while PDE10A selective inhibitors need to have two hydrophobic groups and two hydrogen bond donors to interact with the conservative Tyr693, Gln726, and Phe729 of PDE10A. This study provides valuable insights into the underlying mechanism of selective inhibition targeting PDE9A and PDE10A, for further search for potent and highly selective PDE9A/10A inhibitors.

Indexed as

Models, MolecularAlgorithmsAmino Acid SequenceCatalytic DomainHumansIsoenzymesMolecular ConformationMolecular StructurePhosphodiesterase InhibitorsPhosphoric Diester HydrolasesProtein BindingStructure-Activity RelationshipIsoenzymesPhosphodiesterase InhibitorsPhosphoric Diester HydrolasesMolecular dynamics simulationPhosphodiesteraseQM/MM calculationSelective inhibitor

Identifiers

PMID34907481
OpenAlexW4200103142

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.